Long term survival on haemodialysis in primary hyperoxaluria.
Results of treatment of end-stage renal failure (ESRF) in patients with primary hyperoxaluria have been generally poor, largely due to the inability of any treatment regime to match the endogenous overproduction of oxalate. The severity of the disease varies widely, as reflected by the differences in age at onset of ESRF. This variability may influence the results of treatment of ESRF in these patients. The longest reported survival on haemodialysis of a patient with primary hyperoxaluria is eight and a half years. We report a patient who survived for eleven years on haemodialysis after reaching ESRF due to primary hyperoxaluria, and suggest that this prolonged survival was due to relatively mild disease severity rather than exceptional treatment.
Skinner
R
R
Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, U.K.
Tomson
C R
CR
Tapson
J S
JS
D005260:Female; D006801:Humans; D006959:Hyperoxaluria / Q000628:therapy*; D006960:Hyperoxaluria, Primary / Q000235:genetics / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy*; D008875:Middle Aged; D006435:Renal Dialysis